Crispr Therapeutics (CRSP) | Financial Analysis & Statements
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
35.0M
Gross Profit
-75.2M
-215.00%
Operating Income
-466.6M
-1,333.05%
Net Income
-366.3M
-1,046.43%
EPS (Diluted)
-$4.34
Balance Sheet Metrics
Total Assets
2.2B
Total Liabilities
310.0M
Shareholders Equity
1.9B
Debt to Equity
0.16
Cash Flow Metrics
Operating Cash Flow
-120.8M
Free Cash Flow
-144.7M
Revenue & Profitability Trend
Crispr Therapeutics Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 35.0M | 370.0M | 436.0K | 913.1M | 543.0K |
| Cost of Goods Sold | 110.2M | 130.2M | 110.2M | 101.2M | - |
| Gross Profit | -75.2M | 239.8M | -109.8M | 811.9M | - |
| Operating Expenses | 391.3M | 462.3M | 563.3M | 438.4M | 355.0M |
| Operating Income | -466.6M | -222.5M | -673.2M | 373.5M | -354.4M |
| Pre-tax Income | -362.7M | -150.7M | -650.5M | 379.5M | -348.1M |
| Income Tax | 3.6M | 2.9M | -325.0K | 1.9M | 809.0K |
| Net Income | -366.3M | -153.6M | -650.2M | 377.7M | -348.9M |
| EPS (Diluted) | -$4.34 | -$1.94 | -$8.36 | $4.70 | -$5.29 |
Income Statement Trend
Crispr Therapeutics Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 1.9B | 1.9B | 1.9B | 2.4B | 1.7B |
| Non-Current Assets | 304.9M | 321.5M | 390.0M | 334.4M | 111.3M |
| Total Assets | 2.2B | 2.2B | 2.2B | 2.8B | 1.8B |
| Liabilities | |||||
| Current Liabilities | 87.8M | 108.8M | 121.1M | 119.9M | 94.3M |
| Non-Current Liabilities | 222.2M | 238.0M | 246.5M | 232.5M | 69.5M |
| Total Liabilities | 310.0M | 346.8M | 367.6M | 352.4M | 163.7M |
| Equity | |||||
| Total Shareholders Equity | 1.9B | 1.9B | 1.9B | 2.4B | 1.7B |
Balance Sheet Composition
Crispr Therapeutics Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -366.3M | -153.6M | -650.2M | 377.7M | -348.9M |
| Operating Cash Flow | -120.8M | -263.3M | -502.5M | 515.4M | -281.5M |
| Investing Activities | |||||
| Capital Expenditures | -1.9M | -9.5M | -37.2M | -81.7M | -18.4M |
| Investing Cash Flow | -280.5M | 377.1M | -258.7M | -1.0B | -541.2M |
| Financing Activities | |||||
| Dividends Paid | - | - | - | - | - |
| Financing Cash Flow | 300.7M | 32.7M | 970.0K | 213.3M | 982.3M |
| Free Cash Flow | -144.7M | -272.3M | -532.9M | 457.3M | -256.7M |
Cash Flow Trend
Crispr Therapeutics Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-10.50
Forward P/E
-9.04
Price to Book
2.15
Price to Sales
104.42
PEG Ratio
-9.04
Profitability Ratios
Profit Margin
-215.00%
Operating Margin
-17,158.84%
Return on Equity
-19.71%
Return on Assets
-12.88%
Financial Health
Current Ratio
15.64
Debt to Equity
11.99
Beta
1.74
Per Share Data
EPS (TTM)
-$4.49
Book Value per Share
$21.18
Revenue per Share
$0.44
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| crsp | 3.9B | -10.50 | 2.15 | -19.71% | -215.00% | 11.99 |
| Vertex | 114.1B | 32.82 | 6.92 | -5.64% | -8.91% | 10.00 |
| Regeneron | 55.3B | 13.02 | 1.84 | 15.96% | 31.94% | 9.20 |
| Blueprint Medicines | 8.3B | -120.00 | 24.19 | -47.71% | -27.70% | 208.50 |
| Roivant Sciences | 7.8B | 1.95 | 1.71 | -12.54% | 96.86% | 1.93 |
| Bio-Techne | 7.9B | 60.87 | 3.92 | 6.53% | 10.89% | 20.99 |
Financial data is updated regularly. All figures are in the company's reporting currency.